C20H16ClCuN3O4, triclinic, P1̄ (no. 2), a = 7.629(4) Å, b = 8.893(5) Å, c = 14.193(8) Å, α = 88.603(6)°, β = 81.093(6)°, γ = 83.715(6)°, V = 945.6(9) Å3, Z = 2, Rgt(F) = 0.0245, wRref(F2) = 0.0709, T = 296(2) K
In the title compound, [Cu(C15H11ClN 2O3)(C5H5N)], the hydrazide ligand chelates to the central Cu a...
C14H10CuN4OS, monoclinic, P12(1)/nl (no. 14), a = 8.837(1) angstrom, b = 15.625(2) angstrom, c = 10....
C19H13CuN3O6, monoclinic, P21/c, a = 7.208(3) Å, b = 21.720(8) Å, c = 11.098(5) Å, β = 99.085(17)...
C17H15ClCuN6O2, monoclinic, P121/c1 (No. 14), a = 7.715(3) Å, b = 14.382(2) Å, c = 16.457(3) Å, β = ...
C18H16ClN2O2Cu, monoclinic, C2/c (no. 15), a = 23.330(5) Å, b = 7.1347(14) Å, c = 10.328(2) Å, β = 1...
C16H13Cl2CuN3O3, monoclinic, P21/c (no. 14), a = 11.2656(9) Å, b = 17.1737(14) Å, c = 8.7774(7) Å, β...
In the title compound, [Cu(C21H19N6O2)Cl], the CuII atom is in a slightly distorted square-planar co...
In the title compound, [Cu(C21H19N6O2)Cl], the CuII atom is in a slightly distorted square-planar co...
C47H45Cl2N9Cu3O6, monoclinic, C2/c (no. 15), a = 24.084(9) Å, b = 12.152(5) Å, c = 17.404(7) Å, β = ...
C20H29N3O5, triclinic, P1̄ (no. 2), a = 8.482(6) Å, b = 15.272(12) Å, c = 15.285(12) Å, a = 112.024(...
C28H26CuN2O9, monoclinic, C2/c, a = 12.3146(11) Å, b = 11.1769(10) Å, c = 19.3856(17) Å, β = 101.012...
C22H18N2CuO4, monoclinic, P21/n (no. 14), a = 15.7861(11) Å, b = 5.3211(4) Å, c = 21.6563(16) Å, β =...
The hexanuclear title compound, [{Cu3(μ3-OCH3)(μ-C3H2ClN2)3}2(μ-C3H2ClN2)3(μ6-Cl)] or [Cu6(C3H2ClN2)...
C38H49CuF2N6O9.50, triclinic, P1̄ (no. 2), a = 11.891(2) Å, b = 12.354(3) Å, c = 15.369(3) Å, α = 69...
C11H14Cl4CuN2O, orthorhombic, P212121 (no. 19), a = 7.737(2) Å, b = 10.131(2) Å, c = 20.229(3) Å, V ...
In the title compound, [Cu(C15H11ClN 2O3)(C5H5N)], the hydrazide ligand chelates to the central Cu a...
C14H10CuN4OS, monoclinic, P12(1)/nl (no. 14), a = 8.837(1) angstrom, b = 15.625(2) angstrom, c = 10....
C19H13CuN3O6, monoclinic, P21/c, a = 7.208(3) Å, b = 21.720(8) Å, c = 11.098(5) Å, β = 99.085(17)...
C17H15ClCuN6O2, monoclinic, P121/c1 (No. 14), a = 7.715(3) Å, b = 14.382(2) Å, c = 16.457(3) Å, β = ...
C18H16ClN2O2Cu, monoclinic, C2/c (no. 15), a = 23.330(5) Å, b = 7.1347(14) Å, c = 10.328(2) Å, β = 1...
C16H13Cl2CuN3O3, monoclinic, P21/c (no. 14), a = 11.2656(9) Å, b = 17.1737(14) Å, c = 8.7774(7) Å, β...
In the title compound, [Cu(C21H19N6O2)Cl], the CuII atom is in a slightly distorted square-planar co...
In the title compound, [Cu(C21H19N6O2)Cl], the CuII atom is in a slightly distorted square-planar co...
C47H45Cl2N9Cu3O6, monoclinic, C2/c (no. 15), a = 24.084(9) Å, b = 12.152(5) Å, c = 17.404(7) Å, β = ...
C20H29N3O5, triclinic, P1̄ (no. 2), a = 8.482(6) Å, b = 15.272(12) Å, c = 15.285(12) Å, a = 112.024(...
C28H26CuN2O9, monoclinic, C2/c, a = 12.3146(11) Å, b = 11.1769(10) Å, c = 19.3856(17) Å, β = 101.012...
C22H18N2CuO4, monoclinic, P21/n (no. 14), a = 15.7861(11) Å, b = 5.3211(4) Å, c = 21.6563(16) Å, β =...
The hexanuclear title compound, [{Cu3(μ3-OCH3)(μ-C3H2ClN2)3}2(μ-C3H2ClN2)3(μ6-Cl)] or [Cu6(C3H2ClN2)...
C38H49CuF2N6O9.50, triclinic, P1̄ (no. 2), a = 11.891(2) Å, b = 12.354(3) Å, c = 15.369(3) Å, α = 69...
C11H14Cl4CuN2O, orthorhombic, P212121 (no. 19), a = 7.737(2) Å, b = 10.131(2) Å, c = 20.229(3) Å, V ...
In the title compound, [Cu(C15H11ClN 2O3)(C5H5N)], the hydrazide ligand chelates to the central Cu a...
C14H10CuN4OS, monoclinic, P12(1)/nl (no. 14), a = 8.837(1) angstrom, b = 15.625(2) angstrom, c = 10....
C19H13CuN3O6, monoclinic, P21/c, a = 7.208(3) Å, b = 21.720(8) Å, c = 11.098(5) Å, β = 99.085(17)...